PaxVax appoints new member to board of directors
Connolly current serves on the board of directors of Vaxess Technologies and Aeras. He is also an advisor to the Crossover Healthcare Fund. Connolly previously served as the president and CEO of Aeras, a nonprofit biotechnology company that develops vaccines for tuberculosis and other neglected diseases.
"Jim is a highly respected and successful biopharmaceutical business expert with nearly three decades of commercial experience spanning continents and virtually every corporate function," Kenneth Kelley, the CEO of PaxVax, said. "We are pleased to have him on the PaxVax team. Jim's counsel will be invaluable as we prepare for global regulatory approval and commercialization of our cholera vaccine candidate, PXVX0200 and acquire complementary travelers vaccine assets."
PaxVax's PXVX0200, an oral, single-dose, attenuated cholera vaccine, is currently in Phase III clinical trials. The U.S. Food and Drug Administration granted PXVX0200 fast track designation in response to the lack of an available vaccine against cholera in the U.S.
"PaxVax is poised to become a global leader in the specialty vaccines industry and I am looking forward to working with them at this pivotal stage of growth," Connolly said. "The company's candidate vaccine for cholera addresses an overlooked market and has the potential to provide protection to an estimated 10 million people a year who travel from developed to developing countries where cholera is endemic."
Connolly joins Kelly and other current board members Rich Tong and Rennie Coit from Ignition Capital, retired Major General Philip Russel, and Howie Rosen.